Nasdaq
$0.4160▼ 1.30%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $2.5MShares out 6.1M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
13- 3d agoPre-market26.10.21 20:006-KKey event#●●●#●●●
RedHill Biopharma Ltd.
RedHill Biopharma has terminated its license agreement with Hyloris Pharmaceuticals effective October 15, 2026, by mutual agreement. As a result, the company has regained all ex-North America rights to RHB-102 and will receive a one-time break-up fee of $200,000 from Hyloris.…more
$0.4160-1.30%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 5d agoPre-market26.10.19 21:026-KKey event
RedHill Biopharma Ltd.
RedHill Biopharma's partner, the University of Oklahoma, has been awarded a $2.9 million grant from the National Cancer Institute (NCI). The funding will support Phase 1b and Phase 2 clinical trials evaluating the combination of RedHill's opaganib with CAR T-cell therapy for patients with ultra-high-risk multiple myeloma.…more
$0.4160-1.30%vs prev closeView filingShare - 10.13After-hours26.10.14 05:106-KKey event
RedHill Biopharma Ltd.
RedHill Biopharma has filed a prospectus supplement to increase the aggregate offering amount of its American Depositary Shares (ADSs) by up to $2,587,409 under its existing At-The-Market (ATM) offering agreement with H.C. Wainwright & Co., dated February 3, 2025. This filing enables the company to issue and sell additional shares from time to time utilizing the remaining capacity under its effective Form F-3 registration statement.…more
$0.4160-1.30%vs prev closeView filingShare
12 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 5d agoPre-market26.10.19 21:10#●●●#●●●#●●●
RedHill Biopharma Partners with University of Oklahoma for Opaganib Cancer Clinical Trials…more
RedHill Biopharma's partner, the University of Oklahoma, has received $2.9 million from the National Cancer Institute to conduct clinical trials on the efficacy of opaganib combined with CAR T-cell therapy. The study aims to evaluate whether opaganib can enhance the ability of immune cells to fight cancer in patients.…more
$0.4160-1.30%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.30After-hours26.10.01 05:36
●●●●●●●● ●●●●● ●●●●●●
Redhill Biopharma announced that it generated zero revenue and zero earnings per share for the first half of 2026. The lack of financial performance metrics suggests a neutral outlook for investors.…more
$0.4160-1.30%vs prev closeShareBenzinga - 9.1Pre-market26.09.01 20:05
●●●●●●●● ●●●●● ●●●●●●
RedHill Biopharma has entered an agreement to acquire global commercialization rights for Rebyota and U.S. rights for Clenpiq from Ferring for $12 million upfront. The deal also includes additional milestone payments and tiered royalties based on future performance.…more
$0.4160-1.30%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report